Sökning: onr:"swepub:oai:DiVA.org:uu-472929" > Cytogenetics in Chr...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05241naa a2200541 4500 | |
001 | oai:DiVA.org:uu-472929 | |
003 | SwePub | |
008 | 220422s2022 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:149214695 | |
009 | oai:prod.swepub.kib.ki.se:235392482 | |
009 | oai:prod.swepub.kib.ki.se:154844802 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4729292 URI |
024 | 7 | a https://doi.org/10.1097/HS9.00000000000007072 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1492146952 URI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:2353924822 URI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1548448022 URI |
040 | a (SwePub)uud (SwePub)kid (SwePub)kid (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Baliakas, Panagiotis,d 1977-u Uppsala universitet,Science for Life Laboratory, SciLifeLab,Experimentell och klinisk onkologi,Uppsala Univ Hosp, Dept Clin Genet, Uppsala, Sweden.4 aut0 (Swepub:uu)panba345 |
245 | 1 0 | a Cytogenetics in Chronic Lymphocytic Leukemia :b ERIC Perspectives and Recommendations |
264 | 1 | b Ovid Technologies (Wolters Kluwer Health),c 2022 |
338 | a electronic2 rdacarrier | |
520 | a Mounting evidence underscores the clinical value of cytogenetic analysis in chronic lymphocytic leukemia (CLL), particularly as it allows the identification of complex karyotype, that has recently emerged as a prognostic and potentially predictive biomarker. That said, explicit recommendations regarding the methodology and clinical interpretation of either chromosome banding analysis (CBA) or chromosome microarray analysis (CMA) are still lacking. We herein present the consensus of the Cytogenetic Steering Scientific Committee of ERIC, the European Research Initiative on CLL, regarding methodological issues as well as clinical interpretation of CBA/CMA and discuss their relevance in CLL. ERIC considers CBA standardized and feasible for CLL on the condition that standards are met, extending from the use of novel mitogens to the accurate interpretation of the findings. On the other hand, CMA, is also standardized, however, robust data on its clinical utility are still scarce. In conclusion, cytogenetic analysis is not yet mature enough to guide treatment choices in CLL. That notwithstanding, ERIC encourages the wide application of CBA, and potentially also CMA, in clinical trials in order to obtain robust evidence regarding the predictive value of specific cytogenetic profiles towards refining risk stratification and improving the management of patients with CLL. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Espinet, Blancau Hosp del Mar, Mol Cytogenet Lab, Pathol Dept, Barcelona, Spain.;Inst Hosp del Mar Invest Med IMIM, Canc Res Program, Translat Res Hematol Neoplasms Grp, Barcelona, Spain.4 aut |
700 | 1 | a Mellink, Clemensu Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Clin Genet, Genom Lab, Amsterdam, Netherlands.4 aut |
700 | 1 | a Jarosova, Marieu Masaryk Univ, Fac Med, Inst Med Genet & Genom, Brno, Czech Republic.;Univ Hosp Brno, Brno, Czech Republic.;Masaryk Univ, Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic.;Masaryk Univ, Fac Med, Brno, Czech Republic.4 aut |
700 | 1 | a Athanasiadou, Anastasiau G Papanicolaou Hosp, Hematol Dept, Thessaloniki, Greece.;G Papanicolaou Hosp, HCT Unit, Thessaloniki, Greece.4 aut |
700 | 1 | a Ghia, Paolou IRCCS Osped San Raffaele, Div Expt Oncol, CLL & BCell Neoplasia Unit, Strateg Res Program, Milan, Italy.;Univ Vita Salute San Raffaele, Milan, Italy.4 aut |
700 | 1 | a Kater, Arnon P.u Univ Amsterdam, Amsterdam Univ Med Ctr, Lymphoma & Myeloma Ctr Amsterdam, Dept Hematol,Canc Ctr Amsterdam, Amsterdam, Netherlands.4 aut |
700 | 1 | a Oscier, Davidu Royal Bournemouth Hosp, Dept Haematol, Bournemouth, Dorset, England.4 aut |
700 | 1 | a Haferlach, Claudiau MLL Munich Leukemia Lab, Munich, Germany.4 aut |
700 | 1 | a Stamatopoulos, Kostasu Karolinska Institutet4 aut |
710 | 2 | a Uppsala universitetb Science for Life Laboratory, SciLifeLab4 org |
773 | 0 | t HemaSphered : Ovid Technologies (Wolters Kluwer Health)g 6:4q 6:4x 2572-9241 |
856 | 4 | u https://doi.org/10.1097/HS9.0000000000000707y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1653481/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-472929 |
856 | 4 8 | u https://doi.org/10.1097/HS9.0000000000000707 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:149214695 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:235392482 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:154844802 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy